Patents by Inventor Francois Gessier

Francois Gessier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220041561
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammartory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancer e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
  • Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Publication number: 20200010426
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: September 16, 2019
    Publication date: January 9, 2020
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Patent number: 10457647
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: October 29, 2019
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Publication number: 20180251432
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: May 8, 2018
    Publication date: September 6, 2018
    Inventors: Daniela ANGST, Francois GESSIER, Anna VULPETTI
  • Publication number: 20180140602
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of CD19, e.g., by administering a recombinant T cell comprising the CD19 CAR as described herein, in combination with a BTK inhibitor, e.g., an amino pyrimidine derivative described herein. The invention also provides kits and compositions described herein.
    Type: Application
    Filed: April 7, 2016
    Publication date: May 24, 2018
    Inventors: Daniela Angst, John Byrd, Jason Dubovsky, Joseph A. Fraietta, Francois Gessier, Saar Gill, Amy Johnson, Carl H. June, Marcela Maus, Natarajan Muthusamy, David L. Porter, Marco Ruella, Anna Vulpetti, Mariusz Wasik
  • Patent number: 9512084
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: December 6, 2016
    Assignee: Novartis AG
    Inventors: Daniela Angst, François Gessier, Anna Vulpetti
  • Publication number: 20160235746
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: April 21, 2016
    Publication date: August 18, 2016
    Applicant: NOVARTIS AG
    Inventors: Daniela Angst, François Gessier, Anna Vulpetti
  • Patent number: 9051279
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: February 27, 2013
    Date of Patent: June 9, 2015
    Assignee: Novartis AG
    Inventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, Francois Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
  • Publication number: 20150152068
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Application
    Filed: November 13, 2014
    Publication date: June 4, 2015
    Applicant: NOVARTIS AG
    Inventors: Daniela ANGST, François GESSIER, Anna VULPETTI
  • Publication number: 20130281473
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: February 27, 2013
    Publication date: October 24, 2013
    Inventors: Joerg BERGHAUSEN, Nicole BUSCHMANN, Pascal FURET, Francois GESSIER, Joanna HERGOVICH LISZTWAN, Philipp HOLZER, Edgar JACOBY, Joerg KALLEN, Keiichi MASUYA, Carole PISSOT SOLDERMANN, Haixia REN, Stefan STUTZ
  • Patent number: 8497075
    Abstract: The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7,25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.
    Type: Grant
    Filed: July 12, 2009
    Date of Patent: July 30, 2013
    Assignees: Novartis AG, IRM LLC, Euroscreen SA, The Scripps Research Institute
    Inventors: Birgit Baumgarten, Francois Gessier, Andreas Katopodis, Richard Knochenmuss, Rocco Falchetto, Silvio Roggo, Andreas Sailer, Klaus Seuwen, Carsten Spanka, Juan Zhang, Sebastien Hannedouche, Sophie Noel, Marie-Odile Roy, Yu Chen, Charles Y. Cho, Wei Li, Weijun Shen
  • Patent number: 8440693
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Grant
    Filed: December 20, 2010
    Date of Patent: May 14, 2013
    Assignee: Novartis AG
    Inventors: Joerg Berghausen, Nicole Buschmann, Pascal Furet, François Gessier, Joanna Hergovich Lisztwan, Philipp Holzer, Edgar Jacoby, Joerg Kallen, Keiichi Masuya, Carole Pissot Soldermann, Haixia Ren, Stefan Stutz
  • Publication number: 20130012485
    Abstract: Compounds of the formula (I) are provided: wherein V, W, X, Y, Z, R3, R4, R5, R6, R7 and m are as defined in the specification; and pharmaceutically acceptable salts and prodrugs thereof. The compounds may be useful in the treatment or prevention of various diseases and conditions in which dipeptidylpeptidase-IV (DPP-IV) is implicated.
    Type: Application
    Filed: December 20, 2007
    Publication date: January 10, 2013
    Inventors: Daniel Kaspar Bäschlin, Richard Sedrani, Stefanie Flohr, Kenji Namoto, Nils Ostermann, Finton Sirockin, François Gessier, Garry Fenton, Mandy Christine Beswick, David Edward Clark, Bohdan Waszkowycz
  • Publication number: 20120149661
    Abstract: The invention relates to tetra-substituted heteroarylic compounds of the formula (I) wherein X1, X3 and X4 are independently C or N, Y is C—H, N—H or N, wherein the total number of nitrogen atoms represented by X1, X3, X4 and Y is 1 or 2; rings A and B are independently selected from phenyl or pyridyl; R1, R4, R?, R?, n and m are as defined herein. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: August 24, 2010
    Publication date: June 14, 2012
    Applicant: NOVARTIS AG
    Inventors: Guido Bold, Pascal Furet, Francois Gessier, Joerg Kallen, Joanna Hergovich Lisztwan, Keiichi Masuya, Andrea Vaupel
  • Publication number: 20120077787
    Abstract: New compounds of the Formula (I): for the treatment of non-insulin-dependent diabetes mellitus.
    Type: Application
    Filed: December 6, 2011
    Publication date: March 29, 2012
    Applicant: NOVARTIS AG
    Inventors: Daniel Kaspar Baeschlin, Nils OSTERMANN, Francois GESSIER, Finton SIROCKIN, Kenji NAMOTO
  • Patent number: 8097617
    Abstract: New compounds of the Formula (I): for the treatment of non-insulin-dependent diabetes mellitus.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: January 17, 2012
    Assignee: Novartis AG
    Inventors: Daniel Kaspar Baeschlin, Nils Ostermann, Francois Gessier, Finton Sirockin, Kenji Namoto
  • Publication number: 20110301157
    Abstract: The invention relates to compounds of formula (I) and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in particular tumour diseases.
    Type: Application
    Filed: August 17, 2011
    Publication date: December 8, 2011
    Inventors: Guido Bold, Hans-Georg Capraro, Giorgio Caravatti, Andreas Floersheimer, Pascal Furet, Paul W. Manley, Andrea Vaupel, Carole Pissot Soldermann, Francois Gessier, Christian Schnell, Amanda Jane Littlewood-Evans, Prasad Koteswara Kapa, Joginder S. Bajwa, Xinglong Jiang
  • Publication number: 20110243923
    Abstract: The present invention relates to modulators of the interaction between Epstein-Barr Virus induced receptor-2 (EBi2) and cholest-5-ene-3b,7b,25-triol (7, 25-dihydroxycholesterol) (“7,25DHC”) and/or cholest-5-ene-3b, 7b-diol (7-hydroxycholesterol) (“7HC”). The modulator maybe a small chemical molecule, antibody or other therapeutic protein. Methods of medical treatment and methods of identifying modulators are also described.
    Type: Application
    Filed: July 12, 2009
    Publication date: October 6, 2011
    Inventors: Birgit Baumgarten, Francois Gessier, Andreas Katopodis, Richard Knochenmuss, Rocco Falchetto, Silvio Roggo, Andreas Sailer, Klaus Seuwen, Carsten Spanka, Juan Zhang, Sebastien Hannedouche, Sophie Noel, Marie-Odile Roy, Yu Chen, Charles Y. Cho, Wei Li, Weijun Shen
  • Publication number: 20110230457
    Abstract: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
    Type: Application
    Filed: December 20, 2010
    Publication date: September 22, 2011
    Applicant: NOVARTIS AG
    Inventors: Joerg BERGHAUSEN, Nicole BUSCHMANN, Pascal FURET, François GESSIER, Joanna HERGOVICH LISZTWAN, Philipp HOLTZER, Edgar JACOBY, Joerg KALLEN, Keiichi MASUYA, Carole PISSOT SOLDERMANN, Haixia REN, Stefan STUTZ